Journal of Orthopaedics· 2024Q2
Menisküs Onarımı İçin Bir İskele Olarak Trombositten Zengin Fibrinin (PRF) Kullanışlılığı: Rastgele Olmayan Kontrollü Bir Kohort/Takip Çalışması
Usefulness of platelet-rich fibrin as a scaffold for meniscal repair: A non-randomized controlled cohort/follow-up study
- 4atıf
- Q2SCImago
- 2024yıl
Kısa özet
Trombositten zengin fibrin (PRF) ve trombositten zengin plazma (PRP) ile desteklenen menisküs onarımı cerrahisi, 31 hastada 2 yıl boyunca diz fonksiyon sonuçlarını istatistiksel olarak anlamlı derecede iyileştirmiştir, ancak MRG'de menisküs rejenerasyonu görülmemiştir.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Ana noktalar
- PRF/PRP kullanılan menisküs onarımı cerrahisi, 2 yıl boyunca 31 hastada diz fonksiyon skorlarını anlamlı derecede iyileştirmiştir.
- MRG bulguları onarılan menisküsün rejenerasyonunu göstermemiş, ancak herhangi bir kötüleşme gözlenmemiştir.
- Bir vakada travmatik kıkırdak defektinin ikincil olarak fibrocartilaginöz benzeri doku ile kaplanması gözlemlenmiştir.
- Çalışmada kullanılan PRF ve PRP'nin ortalama trombosit ve beyaz kan hücresi konsantrasyonları sırasıyla yaklaşık 5.5 ve 3.6 kat olmuştur.
Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.
Özet (abstract)
Background: Although regenerative medicine treatment is still in its infancy in Japan, legislation within the past decade has provided opportunities to explore new treatment methods using regenerative medicine. We conducted a 2-year prospective follow-up study to statistically analyze treatment outcomes using platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) as effective scaffolds in meniscal repair.Questions/Purposes.1. Does the use of PRF and PRP for meniscal repair surgery regenerate the meniscus?2. Does augmentation of meniscal repair with PRF effectively improve knee function outcomes? Methods: Thirty-five patients underwent arthroscopic meniscal repair with PRP and PRF using new devices with all-inside techniques. Among these, 31 patients were evaluated for clinical outcomes postoperatively, and magnetic resonance imaging (MRI) findings were evaluated. The variables were coded appropriately by creating a new column based on the Kellgren-Lawrence classification over time. Log transformation of different time points (pre, post 6, 12, or 24 months) in relation to Lysholm, International Knee Documentation Committee (IKDC), Japanese Orthopedic Association (JOA), and Tegner scores were performed. Follow-up arthroscopy using a needle scope was performed in some cases 2 years later. The PRP and PRF used were characterized using the Minimum Information for Studies Evaluating Biologics in Orthopaedics classification. Results: Overall, 31 patients were evaluated (mean age = 39.1 ± 15.7 years; preoperative rehabilitation period = 9.5 ± 7.7 weeks). The PRP had mean platelet and white blood cell concentrations of approximately 5.5- and 3.6-fold, respectively. A significant association existed between sex and deformity deterioration but not in age between the two groups classified by deformity deterioration. Surgical intervention significantly and positively impacted knee function, although no significant changes were found in the activity of the participants over time. MRI findings showed no regeneration of the repaired meniscus; nevertheless, none of them worsened. Furthermore, a case where the traumatic cartilage defect was covered with fibrocartilage-like tissue as a secondary finding was observed. Conclusions: Meniscal repair surgery using PRP/PRF is an effective treatment option for improving knee function in patients with knee deformity. Level of evidence: Level III, Non-randomized controlled cohort/follow-up study.
Yazarların özeti; kaynağından alınmıştır. Journal of Orthopaedics, 2024 · DOI ↗
Ücretsiz hesapla devam et
Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.
Web'de ücretsiz devam etGoogle ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.
Telefonda:
Alan: Cerrahi
SurgeryMedicine